Anterogen Co Ltd 065660
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- KRW 14,200.00–14,500.00
- 52-Week Range
- —–—
- Bid/Ask
- KRW 14,330.00 / KRW 14,330.00
- Market Cap
- KRW 139.45 Bil
- Volume/Avg
- 11,558 / 44,299
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 21.45
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Anterogen Co Ltd is a bio-venture company engaged in the research and development of cell therapy products and orphan drugs using adult stem cells. Its products include Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. The company also offers cell banking services and analysis services that include sample analysis for clinical studies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 35
- Website
- http://www.anterogen.com
Comparables
Valuation
|
Metric
|
065660
|
323990
|
310210
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.09 | 4.36 | 7.78 |
Price/Sales | 21.45 | — | 727.99 |
Price/Cash Flow | — | — | — |
Price/Earnings
065660
323990
310210
Financial Strength
|
Metric
|
065660
|
323990
|
310210
|
|---|---|---|---|
Quick Ratio | 4.99 | 54.78 | 4.85 |
Current Ratio | 5.24 | 55.43 | 4.91 |
Interest Coverage | −2.16 | −260.75 | −18.54 |
Quick Ratio
065660
323990
310210
Profitability
|
Metric
|
065660
|
323990
|
310210
|
|---|---|---|---|
Return on Assets (Normalized) | −3.99% | −29.47% | −42.78% |
Return on Equity (Normalized) | −4.65% | −30.90% | −96.10% |
Return on Invested Capital (Normalized) | −4.80% | −33.70% | −44.97% |
Return on Assets
065660
323990
310210
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hsllrzklks | Jftn | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xhjhqbzhj | Nnjhyx | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sczfvkjk | Ctnzyp | $97.8 Bil | |
MRNA
| Moderna Inc | Fnlqcwxh | Cxq | $38.8 Bil | |
ARGX
| argenx SE ADR | Jttdpsjc | Zrzj | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Wdpzjysr | Yggcq | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zhgvckzc | Nfysfn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pfppfrgf | Zwrbhg | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sxhxchyyt | Yfwzxp | $12.5 Bil | |
INCY
| Incyte Corp | Ntdqnmsn | Jrlrpq | $11.5 Bil |